Europe Neurological Biomarkers Market Share and Forecast by 2027

The European neurological biomarkers market is expected to reach US$ 3,062.94 Mn in 2027 from US$ 1,221.15 Mn in 2019. The market is estimated to grow with a CAGR of 12.4% from 2020-2027.

Biomarkers are the molecules that indicate about the presence of a disease. The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology have enabled to track the health condition of the brain by measuring the biomarkers. This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.

Rapid developments in healthcare and drug discovery sector are leading to the introduction of new therapeutic solutions for the treatment of neurological diseases. Authorities such as World Health Organization, National Institute of Neurological Disorders and Stroke, and National Institutes of Health are taking constructive steps to encourage the research activities and find a remedy for neurological disease treatment.  A biomarker is an indicator of normal biological processes, pathogenic processes, or evaluating a therapeutic intervention. Thus, the discovery of biomarker is an active research area, where a few biomarkers have been sufficiently studied and validated for its use in clinical practice and clinical trials.  Growing research activities in the UK is likely to influence the neurological biomarker market. The Biomarker Research and Imaging for Neuroscience (BRAIN) Centre located in London has a preclinical imaging centre where researchers are focused on developing translational biomarkers of neurological & psychiatric disorders. Furthermore, a research study ‘Protein Variability in Cerebrospinal Fluid and Its Possible Implications for Neurological Protein Biomarker Research’ was conducted in University Bochum, and University Medical Centre Göttingen in Germany and was published in November 2018. Thus, increasing number of research studies conducted in the European region focusing toward advancements in neurological biomarker is expected to augment the growth of the market over the forecast period.

Research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak. This has eventually shifted their focus from development of new neurological biomarkers to vaccine development for COVID-19. Moreover, diversion of resources from neurological biomarkers development to COVID-19 treatment is likely to hamper overall productivity of the drug development during the forecast period. Furthermore, pharmaceutical supplies and procurement are also badly affected by the outbreak of COVID-19 in Europe.

UK Neurological Biomarkers Market Revenue and Forecasts to 2027 (US$ Million)

EUROPE NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION

By Product

• Proteomics Biomarker
• Genomics Biomarker
• Metabolomics Biomarker
• Imaging Biomarker
• Others

By Application

• Alzheimer’s Disease
• Parkinson's Disease
• Schizophrenia
• Huntington's Disease
• Spinal Muscular Atrophy
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostics
• Research Organizations

By Country

• Germany
• UK
• France
• Italy
• Spain

Companies Mentioned

• Thermo Fisher Scientific, Inc
• Abbott
• Merck KGaA
• Myriad Genetics
• QIAGEN

Europe Neurological Biomarkers Report Scope